Prevention of Gonorrhea

Prepared by Brenda L. Beagan, MSc, Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, and Elaine E.L. Wang, MD, CM, FRCPC, Department of Pediatrics, University of Toronto



Objective
To make recommendations about screening and prevention of gonorrhea in Canada.

Burden of Suffering
In 1992, gonorrhea was the second most frequently reported notifiable disease in Canada.  However, the incidence of the disease, which peaked at 56,336 cases in 1981, has decreased steadily to 9,045 cases in 1992. In the U.S., gonorrhea was the most frequently reported sexually transmitted disease with 24% to 30% of cases occurring in adolescents.  Rates per 100,000 dropped from 573 to 327 cases in males and 356 to 230 cases in females between 1981 and 1991.  The incidence of gonorrhea in both countries is particularly high among adolescent populations, with rates as high as 3.5-7.3% among black adolescents in the U.S.  However, the proportion of gonorrhea organisms that are antibiotic-resistant has been increasing.  From 1985 to 1989 the incidence of gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae (PPNG) increased from 0.5% to 5.5% and from less than 1% to 7% in Canada and the U.S., respectively.  Gonococcal infection may be symptomatic, asymptomatic and/or complicated and may involve various anatomical sites.  The majority of patients have anogenital and/or pharyngeal infection.  Local complications may include epididymitis, lymphangitis, penile edema and urethral stricture in men, and salpingitis or pelvic inflammatory disease in women, as well as systemic complications in men or women, including disseminated gonococcal infection, endocarditis and meningitis.  Pelvic inflammatory disease (PID), a serious complication of 10-20% of gonococcal infections, can result in serious medical sequelae such as infertility, ectopic pregnancy, and chronic pelvic pain.

Options
Primary screening options were bacterial cultures and Gram stains. Other measures included serological tests to detect serum antigonococcal antibodies; tests for specific endotoxins, enzymes or fatty acids; enzyme immunoassays; and DNA hybridization techniques. Preventive manoeuvres were abstinence and use of condoms or spermicides. Treatment included antibiotics (oral amoxicillin, ceftriaxone, quinolone and cefixime) and educational interventions.

Outcomes
Sensitivity and specificity of screening measures, relative rate of infection and cure rates associated with antibiotic treatment. Clinical follow-up attendance rates, compliance with medication and willingness to contact all partners were examined in relation to educational interventions.

Evidence
MEDLINE was searched for the years 1981 to January 1994 using the MeSH heading "gonorrhea" with subheadings "complications", "diagnosis", "drug therapy", "epidemiology", "prevention and control", "therapy", and "transmission". Relevant published articles were reviewed, focusing on screening and treatment. Articles about trials were given priority over editorials, case reports, letters or commentaries. Bibliographies of these articles and recent review articles were examined.

Values
The 13-member Task Force of experts in family medicine, geriatric medicine, pediatrics, psychiatry and epidemiology used an evidence-based method for evaluating the effectiveness of preventive health care interventions. Recommendations were not based on cost-effectiveness of options. Patient preferences were not discussed.

Background papers providing critical appraisal of the evidence and tentative recommendations prepared by the chapter author were pre-circulated to the members. Evidence for this topic was presented and deliberated upon in 1- to 2-day meetings, 2 to 3 times per year from November 1991 to March 1994. Consensus was reached on final recommendations.

Benefits, Harms, and Costs
In Canada, 2 factors were found to be predictive in asymptomatic patients: history of contact with a person with a sexually transmitted disease and age < 30 years. A Boston cohort study of 1441 obstetrical/gynecological patients estimated that the risk for infection for women with 1 risk factor (i.e., partner with gonorrhea or urethral discharge, endocervical bleeding induced by swab, 16 yrs at first intercourse, low abdominal or pelvic pain) was 2.5% compared with 0.2% for those with no risk factors.

The accuracy of male urethral specimens is higher than that for female cervical specimens. Stained smears have a specificity of 95% to 100% (all anatomic sites); sensitivity is low for asymptomatic males (50% to 70%), female anogenital infections (45% to 70%) and all pharyngeal and rectal infections. Bacterial cultures have better sensitivity for these 3 groups. Single endocervical cultures have a sensitivity of 80% to 95%. Alternatives to Gram stain and culture have not been studied in an asymptomatic population.

Epidemiological and case-control studies have found that consistent condom use reduces frequency of gonorrhea. There is some epidemiological evidence that spermicidal preparations help prevent infection.

Treatment with antibiotics is 95% effective. Oral amoxicillin is an effective and inexpensive antibiotic if a non-resistant strain is involved. Uncontrolled trials examining antibiotic-resistant strains, found average cure rates of 99.2% for ceftriaxone and 99.5% for 4 different quinolones. Quinolones and cefixime can be administered orally.

3 RCTs evaluated the impact of educational interventions (e.g., educational pamphlets, counselling, intensive counselling, 10-minute videotape) at initial STD visit and found no increase in compliance with medications, willingness to inform sexual contacts, but did find an increase in follow-up attendance.

Recommendations
Recommendation grade [A, B, C, D, E]  and level of evidence [I, II-1, II-2, II-3, III] are indicated after each recommendation. Citations in support of individual recommendations are identified in the guideline text.

Validation
This report was externally peer-reviewed. The 1989 U.S. Preventive Services Task Force recommended routine cultures for persons at high risk. The U.S. Centers for Disease Control recommend diagnosis by culture, and treatment for uncomplicated urogenital or rectal infection with one intramuscular dose of ceftriaxone 250 mg, plus doxycycline 100 mg oral twice daily. The Canadian Laboratory Centre for Disease Control recommends treatment with ceftriaxone plus tetracycline or doxycycline, and screening of high risk groups as well as women who are pregnant, seeking an abortion or IUD insertion.

Sponsors
The Canadian Task Force on Preventive Health Care developed this guideline with funding from Health Canada.

Source Document
Beagan BL, Wang EEL. Prevention of gonorrhea. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994; 720-29.